Comparative Efficacy of Tirzepatide, Teneligliptin, and Empagliflozin in HbA1c Reduction in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The publication is free and its contents are distributed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND 4.0). The rights of the works published in this journal are property of the author and they are free to distribute and disseminate the same sources as long as he correctly cites the font of publication, these acts are not for commercial purposes and no derivative works are generated.
Main Article Content
Abstract
This study’s objective was to evaluate the effectiveness of three different families of drugs (Empagliflozin [an SGLT-2 inhibitor], Tirzepatide [a GLP-1 receptor co-agonist], and Teneligliptin [DPP-4 inhibitor] used in the treatment of type 2 diabetes in lowering HbA1c levels in people with type 2 diabetes mellitus (T2DM). The effectiveness of different families of diabetic drugs was assessed using a meta-analytic approach. Data were gathered from a variety of research publications using ICTRP, CT.gov, and PubMed databases. The data were analyzed, and conclusions were drawn using forest plots. Teneligliptin (a DPP-4 Inhibitor) substantially lowered HbA1c levels in T2DM patients compared to other classes of T2DM drugs with a P-value of 0.0002 and 95% CI -0.63 [-0.97 to -0.30] after reviewing many pertinent articles. The pooled data analysis showed that Tirzepatide and Empagliflozin did not significantly lower HbA1c levels, with the P-value for Tirzepatide being P = 0.55 and for Empagliflozin, it was P = 0.64. According to our research, Teneligliptin may be more effective than Empagliflozin and Tirzepatide as a monotherapy for lowering HbA1c levels in T2DM patients. To corroborate these findings, further research studies are required.
References
Ferrannini, E., Berk, A., Hantel, S. et al. 2013. ‘Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes’, Diabetes Care, 36(12), pp. 4015-4021.
Gerich, J.E. 2010. ‘Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications’, Diabet Med, 27(2), pp. 136-142.
Grempler, R., Thomas, L., Eckhardt, M. et al. 2012. ‘Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors’, Diabetes Obes Metab, 14(1), pp. 83-90.
Guan, R., Yang, Q., Yang, X., Du, W., Li, X. & Ma, G. 2022. ‘Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis’, Front Pharmacol, 13, 998816.
Gupta, S., Shaikh, S., Joshi, P., Bhure, S. & Suvarna, V. 2017. ‘Long-term efficacy and safety of empagliflozin monotherapy in drug-naive patients with type 2 diabetes in Indian subgroup: Results from a 76-week extension trial of phase III, double-blind, randomized study’, Indian J Endocrinol Metab, 21(2), pp. 286-292.
Higgins, J.P., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D. et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. 2011. ‘The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials’, BMJ, 343, d5928.
Isaji, M. 2007. ‘Sodium-glucose cotransporter inhibitors for diabetes’, Curr Opin Investig Drugs, 8(4), pp. 285-292.
Johnston, R., Uthman, O., Cummins, E. et al. 2017. ‘Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation’, Health Technol Assess, 21(2), pp. 1-218.
Karagiannis, T., Avgerinos, I., Liakos, A. et al. 2022. ‘Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis’, Diabetologia, 65(8), pp. 1251-1261.
Kim, M.K., Rhee, E.J., Han, K.A. et al. 2015. ‘Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial’, Diabetes Obes Metab, 17(3), pp. 309-312.
Ndefo, U.A., Anidiobi, N.O., Basheer, E. & Eaton, A.T. 2015. ‘Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes’, P T, 40(6), pp. 364-368.
Otsuki, H., Kosaka, T., Nakamura, K., Shimomura, F., Kuwahara, Y. & Tsukamoto, T. 2014. ‘Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes’, Int Urol Nephrol, 46(2), pp. 427-432.
Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D. et al. 2021. ‘The PRISMA 2020 statement: an updated guideline for reporting systematic reviews’, BMJ, 372, n71.
Palmer, S.C., Tendal, B., Mustafa, R.A. et al. 2021. ‘Sodium-glucose cotransporter protein-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials’, BMJ, 372, m4573.
Richter, B., Bandeira-Echtler, E., Metzendorf, M.I., Hemmingsen, B. 2018. ‘Long-term mono- or dual-combination empagliflozin treatment for adults with type 2 diabetes mellitus’, Cochrane Database Syst Rev, (4), CD013007.
Rosenstock, J., Marquard, J., Laffel, L.M. et al. 2018. ‘Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE Trials’, Diabetes Care, 41(12), pp. 2560-2569.
Toyama, T., Neuen, B.L., Jun, M. et al. 2019. ‘Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis’, Diabetes Obes Metab, 21(5), pp. 1237-1250.
World Health Organization. 2023. ‘Diabetes - Health Topics.’ Available at: https://www.who.int/health-topics/diabetes#tab=tab_1 (Accessed: 23 July 2023).
Zinman, B., Wanner, C., Lachin, J.M. et al. 2015. ‘Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes’, N Engl J Med, 373(22), pp. 2117-2128.